Recent News

• 03.17.2026 - Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.
• 02.26.2026 - Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET

Recent Filings

• 02.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.22.2026 - 4/A Statement of changes in beneficial ownership of securities
• 01.21.2026 - 8-K Current report
• 01.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.21.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.21.2026 - 4 Statement of changes in beneficial ownership of securities